NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.
about
Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD.Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.Advances in umbilical cord blood cell therapy: the present and the future.Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia.Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem ceHaploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission.Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors.National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.Active acute leukaemia: should transplant be offered to all patients?
P2860
Q37684622-DB19CE5F-B1E8-4E2A-A23F-69EA6C1DC73AQ38681322-024819B5-997F-49BD-84E8-C8D3D64077D2Q38734758-6369A7B8-FA2B-48B7-A608-BC2CE5E453E4Q40291317-0051CE6D-1E47-4C88-AE95-8964FC6676CBQ40675515-A29EBC56-1B77-4ED4-A933-BB265ACA3D5CQ41717987-44FA2DD1-CB56-4391-BA9B-6FCF84F30D36Q48359012-2E6EB4FF-5A3D-47E6-8D79-7F7E97F599CCQ48551157-7F5A143A-560D-42A7-9A15-552F289DBC29Q50861552-A833CC85-A2E8-44DB-9C0D-55C10E1B4ED3Q54052781-306409EB-66B2-4994-992C-8688F8FDB3D9
P2860
NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
NIH-defined graft-versus-host ...... acute lymphoblastic leukemia.
@en
NIH-defined graft-versus-host ...... acute lymphoblastic leukemia.
@nl
type
label
NIH-defined graft-versus-host ...... acute lymphoblastic leukemia.
@en
NIH-defined graft-versus-host ...... acute lymphoblastic leukemia.
@nl
prefLabel
NIH-defined graft-versus-host ...... acute lymphoblastic leukemia.
@en
NIH-defined graft-versus-host ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
NIH-defined graft-versus-host ...... acute lymphoblastic leukemia.
@en
P2093
P G Hemmati
P le Coutre
T H Terwey
T M Le Duc
P2860
P304
P356
10.1093/ANNONC/MDS615
P577
2012-12-17T00:00:00Z